Get the Stockscreener App
22.30
7.03%
1.325
Denali Therapeutics Inc stock is traded at $22.30, with a volume of 100.27K.
It is up +7.03% in the last 24 hours and up +4.79% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$20.97
Open:
$22.53
24h Volume:
100.27K
Relative Volume:
0.06
Market Cap:
$3.55B
Revenue:
$1.27M
Net Income/Loss:
$-512.54M
P/E Ratio:
-7.509
EPS:
-2.9691
Net Cash Flow:
$-422.10M
1W Performance:
+13.65%
1M Performance:
+4.79%
6M Performance:
+60.90%
1Y Performance:
+62.53%
1-Day Range:
$22.22
$22.58
1-Week Range:
$19.63
$23.46
52-Week Range:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
22.39 | 3.56B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
452.54 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.05 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
691.35 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
146.63 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Some 13 years and $2 billion later, Denali Therapeutics wins first drug approval - The Business Journals
FDA approves drug to treat neurologic manifestations of Hunter syndrome - The Pharma Letter
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - BioSpace
Denali approval revives surrogate-endpoint path in neuronal MPS - BioCentury
Stifel raises Denali Therapeutics price target on drug approval - Investing.com
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval - Investing.com
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost - Yahoo Finance
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
BTIG raises Denali Therapeutics price target to $38 on drug approval - Investing.com Canada
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy - TipRanks
FDA clears Denali (NASDAQ: DNLI) AVLAYAH therapy for Hunter syndrome - Stock Titan
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH By Investing.com - Investing.com India
FDA approves Denali Therapeutics drug for Hunter syndrome - statnews.com
Oppenheimer raises Denali Therapeutics price target on FDA approval - Investing.com
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval. - Bitget
Denali Therapeutics announces U.S. FDA approval of Avlayah(TM) (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) - marketscreener.com
Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii) - TradingView
Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpStill a Buy? - MarketBeat
US FDA approves Denali's genetic disorder therapy for children - Reuters
Gap Down: Is Denali Therapeutics Inc on track to beat earningsEarnings Trend Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Denali stock gains on FDA nod for lead asset (DNLI:NASDAQ) - Seeking Alpha
Bearish Setup: Why is Denali Therapeutics Inc stock going downQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
Published on: 2026-03-22 06:29:27 - baoquankhu1.vn
Aug Shorts: Can Denali Therapeutics Inc withstand a market correction2026 Retail & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart.com
EV Market: How sensitive is Denali Therapeutics Inc to inflationProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts - MarketBeat
Transcript : Denali Therapeutics Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 03 - marketscreener.com
Price-Driven Insight from (DNLI) for Rule-Based Strategy - Stock Traders Daily
Pharma News: Is Denali Therapeutics Inc stock suitable for long term investing2026 Levels & Weekly Stock Breakout Alerts - baoquankhu1.vn
Holocene Advisors LP Grows Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
1,000,000 Shares in Denali Therapeutics Inc. $DNLI Purchased by Foresite Capital Management VI LLC - MarketBeat
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build - MarketBeat
250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Yahoo Finance
DNLI News & Events - Intellectia AI
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
DNLI: Imminent FDA decision and expanding pipeline highlight strong clinical and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):